×
S&P 500   3,816.66 (-0.13%)
DOW   31,011.18 (+0.21%)
QQQ   283.90 (+0.13%)
AAPL   139.91 (+1.80%)
MSFT   260.76 (+1.67%)
META   163.06 (+1.48%)
GOOGL   2,237.38 (-0.12%)
AMZN   109.65 (+2.09%)
TSLA   674.43 (-3.38%)
NVDA   153.94 (-3.68%)
NIO   21.89 (-2.10%)
BABA   115.77 (-0.85%)
AMD   77.37 (-4.22%)
MU   55.91 (-3.37%)
CGC   3.52 (-2.49%)
T   20.65 (+0.19%)
GE   63.95 (-2.93%)
F   11.49 (-2.71%)
DIS   95.04 (-0.92%)
AMC   13.33 (-0.37%)
PFE   51.10 (+0.87%)
PYPL   71.81 (-0.01%)
NFLX   177.86 (-0.97%)
S&P 500   3,816.66 (-0.13%)
DOW   31,011.18 (+0.21%)
QQQ   283.90 (+0.13%)
AAPL   139.91 (+1.80%)
MSFT   260.76 (+1.67%)
META   163.06 (+1.48%)
GOOGL   2,237.38 (-0.12%)
AMZN   109.65 (+2.09%)
TSLA   674.43 (-3.38%)
NVDA   153.94 (-3.68%)
NIO   21.89 (-2.10%)
BABA   115.77 (-0.85%)
AMD   77.37 (-4.22%)
MU   55.91 (-3.37%)
CGC   3.52 (-2.49%)
T   20.65 (+0.19%)
GE   63.95 (-2.93%)
F   11.49 (-2.71%)
DIS   95.04 (-0.92%)
AMC   13.33 (-0.37%)
PFE   51.10 (+0.87%)
PYPL   71.81 (-0.01%)
NFLX   177.86 (-0.97%)
S&P 500   3,816.66 (-0.13%)
DOW   31,011.18 (+0.21%)
QQQ   283.90 (+0.13%)
AAPL   139.91 (+1.80%)
MSFT   260.76 (+1.67%)
META   163.06 (+1.48%)
GOOGL   2,237.38 (-0.12%)
AMZN   109.65 (+2.09%)
TSLA   674.43 (-3.38%)
NVDA   153.94 (-3.68%)
NIO   21.89 (-2.10%)
BABA   115.77 (-0.85%)
AMD   77.37 (-4.22%)
MU   55.91 (-3.37%)
CGC   3.52 (-2.49%)
T   20.65 (+0.19%)
GE   63.95 (-2.93%)
F   11.49 (-2.71%)
DIS   95.04 (-0.92%)
AMC   13.33 (-0.37%)
PFE   51.10 (+0.87%)
PYPL   71.81 (-0.01%)
NFLX   177.86 (-0.97%)
S&P 500   3,816.66 (-0.13%)
DOW   31,011.18 (+0.21%)
QQQ   283.90 (+0.13%)
AAPL   139.91 (+1.80%)
MSFT   260.76 (+1.67%)
META   163.06 (+1.48%)
GOOGL   2,237.38 (-0.12%)
AMZN   109.65 (+2.09%)
TSLA   674.43 (-3.38%)
NVDA   153.94 (-3.68%)
NIO   21.89 (-2.10%)
BABA   115.77 (-0.85%)
AMD   77.37 (-4.22%)
MU   55.91 (-3.37%)
CGC   3.52 (-2.49%)
T   20.65 (+0.19%)
GE   63.95 (-2.93%)
F   11.49 (-2.71%)
DIS   95.04 (-0.92%)
AMC   13.33 (-0.37%)
PFE   51.10 (+0.87%)
PYPL   71.81 (-0.01%)
NFLX   177.86 (-0.97%)

MarketBeat: Week in Review 5/16 – 5/20

Friday, May 20, 2022 | Chris Markoch

As I sip my Friday morning coffee, it appears that the three major indexes will start in the green. However, where they wind up is anyone’s guess. And the downward pressure on the markets is likely to continue. Next week the latest reading on the Producer Price Index (PPI) will provide more direction. Institutional investors are likely pricing in a hot number so anything that comes in near expectations may calm tensions. Of course, the question you hear from most of the financial news is have we hit bottom yet? If we knew that, investing would be easy. It’s not. But the MarketBeat team is here to help make you a more confident and profitable investor. Our team of analysts stays on top of the market to help you identify buying opportunities or stocks to keep on your watchlist. Here are some of the stocks they were looking at this week.

Articles by Jea Yu

This week Jea Yu pointed investors to three potential buying opportunities in three different sectors. In the healthcare segment, Yu was eyeing Option Care Health (NASDAQ:OPCH).The company is the nation’s largest independent healthcare provider of home and alternate-site infusion services. This includes applications such as antibiotics or chemotherapy. OPCH stock is pulling back as the company continues to manage inflation pressures. And Yu gives investors technical analysis to identify opportunistic entry points. Yu was also looking at the current state of affairs with CarMax (NYSE:KMX). The company is increasing inventory, but inflationary pressure means it’s paying more for that inventory. Still, the company looks well positioned to manage what is likely to be steady demand for used cars. Finally in the consumer staples sector, Yu believes the sell-off may likely be over for WD-40 (NASDAQ:WDFC). The stock is down over 40%, but revenue remains solid and if the company can improve its margins, WDFC stock may present investors with a buying opportunity.


Articles by Thomas Hughes

Thomas Hughes started the week by reminding investors that it’s always wise to follow the money. In writing his article about the three most upgraded stocks to buy, Hughes advises our readers about three stocks that are receiving analyst upgrades. These stocks are most likely to receive institutional dollars which provides a greater probability of success no matter what happens in the market. Hughes was also writing about the S&P 500 index and explains why he believes that a reversal has been confirmed and that investors should be prepare for this index moving much lower from its current level. Turning to specific stocks, Hughes analyzed the earnings report disaster delivered by Target (NYSE:TGT). With an uncertain retail outlook, Target’s solid valuation and 2% dividend yield may not be enough for investors looking for growth in the stock this year.

Articles by Sam Quirke

For much of 2020 and 2021, Disney (NYSE:DIS) has been a difficult stock to own. The reason is that it’s tough for a company to fire on all cylinders when a global pandemic is gumming up the engine. But with the company’s theme parks now open and the company’s streaming service continuing to add subscribers, Sam Quirke believes the worst may be over. That means it may be safe for investors to take a long position in DIS stock. Quirke was also looking at another company that’s been having a rough go of it lately. Specifically, Take-Two Interactive (NASDAQ:TTWO) stock is down 50% since the beginning of 2021.But a double beat on their most recent earnings report may serve to form a level of support from which the stock can move higher.

Articles by Chris Markoch

Solid dividend stocks are never a bad idea. And they’re particularly important at times when investors may be experiencing little to negative stock price growth. A dividend helps increase an investor’s total return. And while that isn’t the only reason Chris Markoch is recommending AbbVie (NYSE:ABBV) stock, it’s not a bad reason. And if investors need more incentive, Markoch points to the company’s recent earnings report which shows that it should be able to manage the loss of revenue as patents expire on its flagship Humira drug. And as investors look for quality stocks to buy, Markoch also believes Deere & Company (NYSE:DE) is a stock to watch. The company is likely to post a double beat on earnings which may solidify the case for a company that is a key player in the agricultural sector.


7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile

Agriculture stocks have a place in every investor's portfolio. The fact is that the byproduct of agriculture literally feeds the world. But for a variety of reasons, supply and/or demand can be disrupted. For example, the weather is often a concern. Farmers are always subject to periods of drought or flooding.

 But the past few years have shown how this sector is not immune from geopolitical concerns. The Covid-19 pandemic affected supply chains on top of seeing demand destruction in key markets. And this year, the world is seeing how interconnected we've become. Russia's war on Ukraine is shutting in a large percentage of the world's wheat supply.

However, with commodity prices soaring in several categories, investors have an opportunity in agriculture technology stocks. These companies run the gamut from companies that provide equipment to those that provide fertilizer, pesticides, and other products and services.

To help investors determine if this opportunity is right for them, we've created this special presentation. We assess the long-term opportunity for seven agricultural technology stocks.



View the "7 Agricultural Technology Stocks to Buy as Commodity Prices Remain Volatile".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastHow to Profit In The Bear Market

Today, Kate is joined by a repeat guest, Rob Isbitts of Sungarden Investment Publishing. Rob specializes in ETF portfolios designed to deliver returns in any kind of market condition, including the current bear. In this conversation, Rob gives specific ideas for handling various allocations in your portfolio, and discusses how to approach inverse ETFs.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.